Literature DB >> 33284795

In silico mutagenesis of human ACE2 with S protein and translational efficiency explain SARS-CoV-2 infectivity in different species.

Javier Delgado Blanco1, Xavier Hernandez-Alias1, Damiano Cianferoni1, Luis Serrano1,2,3.   

Abstract

The coronavirus disease COVID-19 constitutes the most severe pandemic of the last decades having caused more than 1 million deaths worldwide. The SARS-CoV-2 virus recognizes the angiotensin converting enzyme 2 (ACE2) on the surface of human cells through its spike protein. It has been reported that the coronavirus can mildly infect cats, and ferrets, and perhaps dogs while not pigs, mice, chicken and ducks. Differences in viral infectivity among different species or individuals could be due to amino acid differences at key positions of the host proteins that interact with the virus, the immune response, expression levels of host proteins and translation efficiency of the viral proteins among other factors. Here, first we have addressed the importance that sequence variants of different animal species, human individuals and virus isolates have on the interaction between the RBD domain of the SARS-CoV-2 spike S protein and human angiotensin converting enzyme 2 (ACE2). Second, we have looked at viral translation efficiency by using the tRNA adaptation index. We find that integration of both interaction energy with ACE2 and translational efficiency explains animal infectivity. Humans are the top species in which SARS-CoV-2 is both efficiently translated as well as optimally interacting with ACE2. We have found some viral mutations that increase affinity for hACE and some hACE2 variants affecting ACE2 stability and virus binding. These variants suggest that different sensitivities to coronavirus infection in humans could arise in some cases from allelic variability affecting ACE2 stability and virus binding.

Entities:  

Year:  2020        PMID: 33284795     DOI: 10.1371/journal.pcbi.1008450

Source DB:  PubMed          Journal:  PLoS Comput Biol        ISSN: 1553-734X            Impact factor:   4.475


  14 in total

1.  Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2.

Authors:  Bo Wang; Eric R Gamazon
Journal:  iScience       Date:  2022-06-02

2.  Should we discount the laboratory origin of COVID-19?

Authors:  Rossana Segreto; Yuri Deigin; Kevin McCairn; Alejandro Sousa; Dan Sirotkin; Karl Sirotkin; Jonathan J Couey; Adrian Jones; Daoyu Zhang
Journal:  Environ Chem Lett       Date:  2021-03-25       Impact factor: 13.615

3.  Mutational analysis of structural proteins of SARS-CoV-2.

Authors:  Shweta Jakhmola; Omkar Indari; Dharmendra Kashyap; Nidhi Varshney; Ayan Das; Elangovan Manivannan; Hem Chandra Jha
Journal:  Heliyon       Date:  2021-03-20

Review 4.  Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets.

Authors:  Max Maurin; Florence Fenollar; Oleg Mediannikov; Bernard Davoust; Christian Devaux; Didier Raoult
Journal:  Microorganisms       Date:  2021-04-17

5.  Variation in predicted COVID-19 risk among lemurs and lorises.

Authors:  Amanda D Melin; Joseph D Orkin; Mareike C Janiak; Alejandro Valenzuela; Lukas Kuderna; Frank Marrone; Hasinala Ramangason; Julie E Horvath; Christian Roos; Andrew C Kitchener; Chiea Chuen Khor; Weng Khong Lim; Jessica G H Lee; Patrick Tan; Govindhaswamy Umapathy; Muthuswamy Raveendran; R Alan Harris; Ivo Gut; Marta Gut; Esther Lizano; Tilo Nadler; Dietmar Zinner; Steig E Johnson; Erich D Jarvis; Olivier Fedrigo; Dongdong Wu; Guojie Zhang; Kyle Kai-How Farh; Jeffrey Rogers; Tomas Marques-Bonet; Arcadi Navarro; David Juan; Paramjit S Arora; James P Higham
Journal:  bioRxiv       Date:  2021-02-03

6.  E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody.

Authors:  Sandipan Chakraborty
Journal:  Int Immunopharmacol       Date:  2021-12-03       Impact factor: 4.932

7.  Human Ace D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19.

Authors:  Elifcan Aladag; Zahit Tas; Bilgesu Safak Ozdemir; Tayfun Hilmi Akbaba; Meltem Gulsun Akpınar; Hakan Goker; Tugce Unalan-Altintop; Ahmet Cagkan Inkaya; Alpaslan Alp; Gokhan Metan; Ibrahim Celalettin Haznedaroglu; Banu Balci-Peynircioglu; Nilgun Sayinalp
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-09-15       Impact factor: 1.636

8.  A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues.

Authors:  Chen Chen; Veda Sheersh Boorla; Ratul Chowdhury; Ruth H Nissly; Abhinay Gontu; Shubhada K Chothe; Lindsey LaBella; Padmaja Jakka; Santhamani Ramasamy; Kurt J Vandegrift; Meera Surendran Nair; Suresh V Kuchipudi; Costas D Maranas
Journal:  bioRxiv       Date:  2022-03-23

9.  Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2.

Authors:  Jingsong Zhang; Yang Zhang; Jun-Yan Kang; Shuiye Chen; Yongqun He; Benhao Han; Mo-Fang Liu; Lina Lu; Li Li; Zhigang Yi; Luonan Chen
Journal:  Cell Discov       Date:  2021-06-15       Impact factor: 10.849

Review 10.  Exploring the therapeutic potential of marine-derived bioactive compounds against COVID-19.

Authors:  Rachana Singh; Niketa Chauhan; Mohammed Kuddus
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-02       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.